Thank you, Eva, and thank you all for joining us this morning. Before turning to our fourth quarter results, I would like to ...

Moby Strategic Pillars and Performance Drivers. Management characterizes 2025 as a foundational year of disciplined e ...

Creative Biolabs’ expanded primary neuron portfolio includes cortical, hippocampal, dopaminergic, and sensory neurons isolated and characterized under stringent quality control (QC) standards and ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual ...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 ...

From 4L80E and Allison six-speeds to the 10R80 and Gear Vendors, these overdrive transmissions reshaped street performance, ...

Apellis Pharmaceuticals APLS reported fourth-quarter 2025 loss of 47 cents per share, wider than the Zacks Consensus Estimate of a loss of 39 cents. The company had incurred a loss of 29 cents in ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

A team of researchers have come to the conclusion that cities are warming much faster than the surrounding countryside, the ...

A woman in her 20s with a mechanical mitral valve replacement on long-term warfarin therapy presented with frank haematuria and acute kidney injury (AKI). The initial clinical impression was ...